Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind Phase III Study of MRA-SC in Rheumatoid Arthritis
jRCT2080221083Phase 3
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Apr 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tocilizumab in rheumatoid arthritis (RA) (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2080221083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221083.